Sign in to continue:

Wednesday, March 4th, 2026

Sundart Holdings Limited to Announce 2025 Annual Results and Final Dividend on March 19, 2026

Sundart Holdings Limited Announces Board Meeting for 2025 Annual Results and Dividend Declaration

Sundart Holdings Limited Schedules Board Meeting to Approve 2025 Annual Results and Final Dividend

Key Highlights for Investors

  • Scheduled Board Meeting: Sundart Holdings Limited has announced that its Board of Directors will hold a meeting on Thursday, 19 March 2026, at 11:30 a.m. The meeting will take place at 19/F, Millennium City 3, 370 Kwun Tong Road, Kowloon, Hong Kong.
  • Purpose of the Meeting:
    • To consider and approve the audited consolidated results of the Group for the year ended 31 December 2025 (the “2025 Annual Results”).
    • To approve the publication of the announcement of the 2025 Annual Results.
    • To consider the declaration of a final dividend for shareholders.
  • Key Directors Involved:
    • The executive Directors are Mr. Ng Tak Kwan (Chief Executive Officer), Mr. Ng Chi Hang, Mr. Ding Jingyong, Mr. Guan Yihe, and Mr. Xie Jianyu.
    • Non-executive Director: Mr. Liu Zaiwang.
    • Independent non-executive Directors: Ms. Tam Yin Ming Cecilia, Mr. Huang Pu, and Mr. Li Zheng.

Important Information for Shareholders

  • Potential Price-Sensitive Event: The Board will consider the declaration of a final dividend for the financial year ended 31 December 2025. The announcement of the annual results and the final dividend are both events that can significantly affect the company’s share price, as they provide insights into the company’s financial performance and return to shareholders.
  • Timing of Results: Investors should pay close attention to the outcome of the meeting on 19 March 2026, as the release of annual results and any declared dividend will likely influence market sentiment and trading activity in the company’s shares.

What Investors Should Watch For

  • Financial Performance: The approval and subsequent publication of the 2025 audited results will offer a comprehensive view of Sundart Holdings Limited’s operational and financial performance over the past year.
  • Dividend Declaration: The Board’s decision regarding the final dividend will directly impact shareholder returns and could be a key catalyst for the company’s share price.
  • Leadership and Corporate Governance: The announcement reaffirms the company’s leadership team and independent oversight, which may be relevant for corporate governance considerations.

Conclusion

The upcoming Board meeting and the anticipated announcement of the 2025 Annual Results and final dividend represent key events for Sundart Holdings Limited and its shareholders. Investors are advised to monitor these developments closely, as they may have material impacts on the company’s valuation and future prospects.


Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should exercise their own judgment and consult with financial advisors before making investment decisions. The company’s actual performance and dividend declaration may differ from expectations, and past performance is not indicative of future results.


View SUNDART HLDGS Historical chart here



Abbisko Therapeutics Begins Phase I/II Clinical Trial of Oral KRAS G12D Inhibitor ABSK141 for Advanced Solid Tumors 12

Abbisko Therapeutics Announces First Patient Dosing in KRAS G12D Clinical Trial: Key Details for Investors Abbisko Therapeutics Completes First Patient Dosing in KRAS G12D Phase I/II Clinical Trial Summary of Key Points First patient...

Disclosure of Share Dealings in ENN Energy Holdings Limited by Morgan Stanley Capital Services LLC During Privatisation Scheme

ENN Energy Holdings – Securities Dealings Disclosure Key Disclosure: Securities Dealings Related to ENN Energy Holdings Limited Privatisation Summary of Disclosure On 27 February 2026, the Executive received a public disclosure under Rule 22...

CStone’s Sugemalimab Receives UK MHRA Approval for Stage III NSCLC, Expanding Global Oncology Footprint

CStone Pharmaceuticals: Sugemalimab Receives UK MHRA Approval for Stage III NSCLC CStone Pharmaceuticals: Sugemalimab Receives UK MHRA Approval for Stage III NSCLC Key Highlights Sugemalimab, CStone’s innovative anti-PD-L1 monoclonal antibody, has received a new...

   Ad